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Biological tissues require oxygen to meet their energetic demands. However, the consumption of oxygen also results in the
generation of free radicals that may have damaging eﬀects on cells. The brain is particularly vulnerable to the eﬀects of reactive
oxygenspeciesduetoitshighdemandforoxygen,anditsabundanceofhighlyperoxidisablesubstrates.Oxidativestressiscausedby
an imbalance in the redox stateof thecell, either byoverproduction of reactive oxygen species, or by dysfunction of the antioxidant
systems. Oxidative stress has been detected in a range of neurodegenerative disease, and emerging evidence from in vitro and in
vivo disease models suggests that oxidative stress may play a role in disease pathogenesis. However, the promise of antioxidants
as novel therapies for neurodegenerative diseases has not been borne out in clinical studies. In this review, we critically assess the
hypothesis that oxidative stress is a crucial player in common neurodegenerative disease and discuss the source of free radicals
in such diseases. Furthermore, we examine the issues surrounding the failure to translate this hypothesis into an eﬀective clinical
treatment.
1.Introduction
1.1. Oxidative Stress and Neurodegeneration. It has been long
recognised that oxidative stress may be important in the aeti-
ology of a variety of late onset neurodegenerative diseases.
Aging has been established as the most important risk factor
for the common neurodegenerative diseases, Alzheimer’s
disease (AD), and Parkinson’s disease (PD). Most theories of
aging centre are on the idea that cumulative oxidative stress
leads to mitochondrial mutations, mitochondrial dysfunc-
tion, and oxidative damage [1]. However, as the role of ROS
becomes increasingly recognised in aging and age-related
diseases, a number of controversies begin to emerge in this
ﬁeld. Is oxidative stress an epiphenomenon of dysfunctional
and dying neurons, or does oxidative stress itself cause
the dysfunctionality/death of neurons? How does a global
event such as oxidative stress result in the selective neuronal
vulnerability seen in most neurodegenerative diseases? And
ﬁnally,ifoxidativestressistrulyfundamentaltopathogenesis
then why has the use of antioxidant therapy been thus far
largely unsuccessful in such diseases?
In order to address these questions, we ﬁrst outline the
deﬁnition of oxidative stress and show how ROS is generated
in the human brain (Box 1), as well as the antioxidant
defence mechanisms that exist to counteract it (Box 2). We
present the evidence that oxidative stress can be found in ne-
urodegenerative disease. Next we address the issue of whe-
ther oxidative stress is truly pathogenic in disease models. In
order to prove a crucial of ROS, it is necessary to observe
oxidative stress as an early event in the disease process, and
to further demonstrate that inhibition of ROS production
is able to prevent the pathogenic process. We describe the
evidence from animal and cellular models of the role of
ROS in the major neurodegenerative diseases. We present
hypotheses for the interplay between oxidative stress and
selective cell death. Finally we study the rationale for the use
of antioxidant therapy and the outcome of its use in human
disease. Although oxidative stress has been implicated in
a range of chronic neurodegenerative disorders, including
Alzheimer’s disease, Parkinson’s disease, Huntington’s dis-
ease, and Amyotrophic Lateral Sclerosis, the two commonest
of these diseases, AD and PD, will be discussed in detail2 Oxidative Medicine and Cellular Longevity
in this review, and other neurodegenerative diseases will be
referenced where relevant.
2. What Is OxidativeStress?
Oxygen is essential for the normal function of eukaryotic
organisms. Its role in survival is linked to its high redox
potential,whichmakesitanexcellentoxidizingagentcapable
of accepting electrons easily from reduced substrates. Diﬀer-
ent tissues have diﬀerent oxygen demands depending on
their metabolic needs. Neurons and astrocytes, the two
major types of brain cells, are largely responsible for the
brain’s massive consumption of O2 and glucose; indeed, the
brain represents only ∼2% of the total body weight and yet
accounts for more than 20% of the total consumption of
oxygen [2]. Despite the essentiality of oxygen for living orga-
nisms, the state of hyperoxia produces toxicity, including
neurotoxicity [3, 4]. The toxicity and chemical activity of
oxygen depends on its electronic structure. The identical
spin states of its two outer orbital electrons render oxygen
kinetically stable, except in the presence of appropriate
catalyststhatscrambleelectronspinstatestoproducepartial-
ly reduced forms of oxygen. Partially reduced forms of
oxygen are highly active because the free radical is very un-
stable and must either accept or be a donor of electrons.
There are many diﬀerent varieties of partially reduced re-
active oxygen species (ROS) including superoxide (O
•−
2 ), hy-
drogen peroxide (H2O2), and the hydroxyl radical (OH•).
The modern use of the term “ROS” includes both oxygen
radicals and nonradicals that are easily converted into free
radicals (O3,H 2O2, 1O2)[ 2]. ROS have diﬀerent reactive
abilities, and one of the most reactive ROS is the hydroxyl
radical OH•. Due to the high reactive activity of ROS,
they chemically interact with biological molecules leading to
changes in cell function and cell death. As a result, oxygen
has the potential to be poisonous, and aerobic organisms
survive its presence only because they contain antioxidant
defences [5]. Brain cells and especially neurons require eﬀec-
tive antioxidant protection for several reasons.
(1) They exhibit higher (about 10-fold) oxygen con-
sumption compared to other tissues.
(2) Nondividing cells such as neurons have a long life
duration.
(3) Nitricoxidehasaprominentroleinthebrainandcan
form reactive nitrogen species such as peroxynitrite,
in combination with some forms of oxygen such as
superoxide. Nitric oxide may take part in nitrosyla-
tion of proteins; however, peroxynitrite is a highly
reactive nitrogen species that can nitrate tyrosine
residues of proteins and alter their function.
Oxidative stress is a condition in which the balance
between production of ROS and level of antioxidants is sig-
niﬁcantly disturbed and results in damage to cells by the
excessive ROS. ROS contribute to the development of neu-
rodegeneration by modulating the function of biomolecules.
ROS may target several diﬀerent substrates in the cell, caus-
ing protein, DNA, RNA oxidation, or lipid peroxidation
(Figure 1). The oxidation products of polyunsaturated fatty
acids, especially arachidonic acid and docosahexanoic acid
which are abundant in brain, are malondialdehyde and 4-
hydroxynonenal. ROS attacks protein, oxidising both the
backboneandthesidechain,whichinturnreactswithamino
acid side chains to form carbonyl functions. ROS attacks
nucleic acids in a number of ways, causing DNA-protein
crosslinks, breaks in the strand, and modiﬁes purine and
pyridine bases resulting in DNA mutations.
2.1. Oxidative Stress Occurs in Neurodegenerative Disease.
Alzheimer’s disease is the most common neurodegenerative
disease, aﬀecting approximately 16 million people world-
wide.Itischaracterisedbyprogressiveneuronallossassociat-
ed with aggregation of protein as extracellular amyloid (βA)
plaques, and intracellular tau tangles. AD brains also show
evidence of ROS mediated-injury; there is an increase in
levels of malondyaldehyde and 4-hydroxynonenal in brain
and cerebrospinal ﬂuid of AD patients compared to controls
[6].Proteincarbonylmoietiesareincreasedinthefrontaland
parietalcortices,andhippocampusinADbrain,withsparing
of the cerebellum where no AD pathology occurs [7, 8].
There is also an increase in hydroxylated guanine in AD sam-
ples compared to age-matched controls [9, 10]. This data
from human brain is also supported by data from transgenic
animal models of AD in which markers of protein and lipid
peroxidation are increased in the cortex and hippocampus
prior to the appearance of plaques or tangle pathology [11].
Parkinson’s disease is the second most common neu-
rodegenerative disease and is characterised by progressive
loss of dopaminergic neurons in the substantia nigra, and
aggregation of the protein α-synuclein. In PD brain, the
concentration of polyunsaturated free fatty acids in the sub-
stantia nigra is reduced, while the levels of lipid peroxida-
tion markers (malondialdehyde and 4-hydroxynonenal) are
increased [12]. Protein oxidative damage in the form of
protein carbonyls [13] is also evident in PD brain compared
to controls, and there is some evidence to suggest a role for
nitration and nitrosylation of certain proteins due to reactive
nitrogen species in PD brain [14]. In addition to increased
levels of 8-hydroxydeoxyguanosine in PD brain [15], it has
been reported that there is an increase in the common dele-
tions in mitochondrial DNA in the surviving dopaminergic
neurons in PD substantia nigra. Such deletions are believed
to be the result of oxidative stress [16].
2.2. Mechanisms of Oxidative Stress: ROS Production by Mito-
chondrial Dysfunction. Mitochondrial pathology is evident
in many neurodegenerative diseases including AD, PD, Hun-
tington’s disease, ALS, PSP, Friedreich’s ataxia, Neurodegen-
eration with brain iron accumulation, and optic atrophy.
The spectrum of mitochondrial dysfunction is vast and in-
cludes respiratory chain dysfunction and oxidative stress,
reduced ATP production, calcium dysregulation, mitochon-
drial permeability transition pore opening, peturbation in
mitochondrial dynamics, and deregulated mitochondrial
clearance. As many of the functions of the mitochondria are
interdependent, many of these pathologies exist together in
varying degrees in the diﬀerent disorders.Oxidative Medicine and Cellular Longevity 3
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Figure 1: Schematic diagram of main producers of ROS and antioxidant system in neurons and glia. Main ROS producers are shown
in red: monoamine oxidase (MAO), complex I and III are major sources within mitochondria. ROS generated in mitochondria target
the permeability transition pore (PTP), PARP, and mitochondrial DNA. In the cytosol, NADPH oxidase (NOX) and xanthine oxidase
(XO) are the main producers of ROS. The major antioxidant systems are shown in green and include superoxide dismutase (SOD) in
the mitochondria, glutathione (GSH), catalase (C), and glutathione peroxidase (GPx).
The greatest interest in mitochondrial dysfunction and
mitochondrial ROS production has been in PD, as demon-
strated in human brain, as well as both the toxin and
genetic disease models. A reduction in complex I activity has
beendemonstratedinthesubstantianigra,lymphocytes,and
platelets of PD patients (reviewed in [17]). The neurotoxin
1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) has
been shown to produce parkinsonian symptoms in primates
and rodents, and it has therefore been extensively used
as an animal model of Parkinson’s disease. Studies have
indicated that l-methyl-4-phenylpyridinium (MPP+), the
active metabolite of MPTP, can block electron transport by
binding to the same site as the classic Complex I inhibitor,
rotenone, leading to a loss of ATP production. Rotenone or
MPP+ also produces superoxide anions in submitochondrial
particles, adding further support to the basic premise that
MPP+ acts primarily as a mitochondrial toxin [18, 19]. The
neurotoxic eﬀects of MPP+ and rotenone are likely to be
duetooxidativestressratherthanmetabolicchangesbecause
they can be eﬀectively prevented by antioxidants [20]. Mild
uncoupling of mitochondria with UCP2 overexpression
reduces ROS production in toxic (MPP+,r o t e n o n e )m o u s e
modelsofParkinson’sdisease.UCP2deﬁciencyalsoincreases
thesensitivityofdopamineneuronstoMPTP,whereasUCP2
overexpression decreases MPTP-induced nigral dopamine
cell loss [21].
The identiﬁcation of a number of PD-related genes that
are strongly associated with mitochondrial function (PINK1,
DJ-1, Parkin) further adds weight that mitochondrial dys-
function with resultant oxidative stress is a primary event
in PD pathogenesis. Loss of function of DJ-1 results in
oxidative stress, and DJ-1 exerts neuroprotection via its
antioxidant mechanism in mitochondria [22, 23]. Mutations
in PINK1 cause a recessive form of PD. PINK1 is a mito-
chondrial kinase, and we and other authors have previously
demonstrated that PINK1 deﬁciency results in impaired res-
piration with inhibition of complex 1, reduced substrate
availability, and rotenone-like increased production of ROS
in mitochondria [24–26]. PINK1 deﬁciency also results in
an inability to handle cytosolic calcium challenges due to
an impairment of mitochondrial calcium eﬄux, that leads
to mitochondrial calcium overload. A combination of ROS
production and mitochondrial Ca2+ initiates opening of
mitochondrial permeability transition pore (PTP), which
allows translocation of proapoptotic molecules from the
mitochondria to the cytosol, in order to trigger apoptotic
cell death [27, 28]. Early opening of the PTP has been de-
monstrated in PD models, for example, the toxic (MPP+)
model and the genetic PINK1 deﬁciency model [24, 29].
PINK1 deﬁciency also results in abnormal mitochondrial
morphology reﬂecting an altered balance of mitochondrial
ﬁssion/fusion, and in Drosophila models PINK1 appears
to genetically interact with the mitochondrial ﬁssion/fusion
machinery proteins. More recently an emerging function of
PINK1 has been its concerted action with parkin in the regu-
lation of clearance of damaged mitochondria via autophagy.4 Oxidative Medicine and Cellular Longevity
Loss of the mitochondrial membrane potential stabilises
PINK1 expression, leading to PINK1-dependent recruitment
of parkin to the mitochondria. Ubiquitination of a number
of substrates by parkin then activates the autophagy of dam-
aged mitochondria. Mutations in either parkin or PINK1
thus result in a failure of mitophagy, and an accumulation of
dysfunctional mitochondria with increased ROS production,
furtherincreasingtheoxidativestressontheneuron[30–32].
Abnormal aggregation of protein is a characteristic
feature of neurodegenerative disease, and it appears that mi-
tochondrial dysfunction and ROS production may inﬂuence
the aggregation of the protein, α-synuclein, which accu-
mulates in all PD brain. Mutations in α-synuclein gene
cause a familial form of autosomal dominant PD. Expres-
sion of mutant α-synuclein in mouse models or neurons
results in mitochondrial dysfunction and increased ROS
production [33, 34]. However, protein oxidation induced
by mitochondrial ROS production is also required for α-
synuclein oligomerization [35]a n dt o x i c i t y .α-synuclein
has recently been shown to bind to mitochondria and in-
duce mitochondrial fragmentation through the inhibition
of membrane fusion, a phenotype that interestingly can be
rescued by coexpression of the mitochondrial PD proteins
PINK1, DJ-1, and parkin [36].
Mitochondrial dysfunction and ROS production may
playaroleinthepathogenesisofAD.Areductionincomplex
IV activity has been demonstrated in mitochondria from
the hippocampus and platelets of AD patients, as well as in
AD animal models and AD cybrid cells in reviewed [37].
Accumulation of βA leads to oxidative stress, mitochondrial
dysfunction, and energy failure prior to the development of
plaque pathology [38]. Deregulation of calcium homeostasis
has been demonstrated in AD, with βA causing increased
cytoplasmic calcium levels and mitochondrial calcium over-
load, resulting in increase in ROS production and opening
of the PTP [39, 40]. βA is able to induce opening of PTP in
isolated mitochondria [41, 42] and primary astrocytes [43–
45].FurthermoreβAmaydirectlyinteractwithcyclophilinD
(a PTP component) forming a complex in the mitochondria
that has reduced threshold for opening in the presence of
mPTP inducers. Prevention of PTP opening by inducing
cyclophilin D deﬁciency (molecular inhibition of PTP open-
ing) is also able to improve mitochondrial function and
learning/memory in an aging Alzheimer’s disease mouse
model [46]. A peturbation in mitochondrial dynamics has
also been described in AD human brain and cell models.
Fragmented mitochondria are seen in AD hippocampus in
association with a downregulation of mitochondrial fusion
proteins (MFN-1, MFN-2, OPA-1), with an increase in ex-
pression of the mitochondrial ﬁssion protein Fis-1 [47].
2.3. Mechanisms of Oxidative Stress: ROS Production via
NADPH Oxidase. Although there are several diﬀerent pro-
posed mechanisms of neurodegeneration in Alzheimer’s
Disease (AD), there is good evidence for the presence of oxi-
dative stress and the involvement of NADPH oxidase in this
disease.ActivationofNOX2hasbeendemonstratedinbrains
of AD patients [48], with upregulation of NOX1 and NOX3
in early stage postmortem AD brain [49].
The crucial role for NADPH oxidase in AD has also
been conﬁrmed in animal models. Thus, NOX2 deﬁciency
improved the outcome in a mouse model of AD. Mice
that overexpress the Swedish mutation of APP (Tg2576,
which leads to Aβ fragment accumulation) were crossed
with NOX2-deﬁcient mice. In this model, the absence of
functional NOX2 was protective and prevented the negative
eﬀects of βA deposition. Neuronal oxidative stress was abro-
gated, and behavioural deﬁcits improved in both young and
aged Tg2576/NOX2-deﬁcient mice [50, 51].
The role of NADPH oxidase in AD has also been sug-
gested at a cellular level. Amyloid-beta (βA) induced direct
activation of NADPH oxidase in rat primary culture of
microglial cells and human phagocytes [52]. βAa c t i v a t e s
microglial NOX through B-class scavenger receptor CD36
[53]. Active NADPH oxidase transfers protons across the
membrane and, for normal functioning, requires opening of
an ion/anion channel for charge compensation [54]. In βA-
activated microglia, inhibition of CLIC1 channel inhibited
superoxide production and protected cells by blocking the
charge compensatory mechanism of NADPH oxidase [55].
βA-induced stimulation of NADPH oxidase may damage
surrounding cells because it occurs in combination with
massive NO production and the generation of peroxynitrate
[56, 57]. Neuroprotective eﬀect of some endogenous com-
pounds, such a hormone melatonin is induced by its anti-
oxidant properties [58, 59].
βA also activates NADPH oxidase by inducing calcium
entryintoastrocytesbutnotneurons[39,40].Theactivation
of NADPH oxidase results in the generation of oxidative
stress, which depolarises the mitochondrial membrane and,
in combination with calcium, induces opening of the mito-
chondrialpermeabilitytransitionpore(mPTP;Figure 1)[43,
45] as well as changing membrane structure through activa-
tion of phospholipase C [60]. This oxidative stress signal is
passed to neighbouring neurons, which are more vulnerable
than astrocytes. The mechanism by which this occurs is not
certain although neuronal production of glutathione, a key
antioxidant, requires glutathione precursors derived from
extracellularcleavageofglutathionereleasedfromastrocytes.
It has therefore been suggested that depletion of GSH in
astrocytes due to increased oxidant production by NADPH
oxidasecoulddiminishGSHreleasefromastrocytesandcon-
sequently deplete GSH in neurons [43, 44]. There is much
less information available regarding the direct activation of
NADPH oxidase in neurons in AD models although there is
some evidence that βA and the presenilins exhibit the ability
to activate NADPH oxidase in primary neurons [61–63].
In Parkinson’s disease (PD), oxidative stress has been
demonstratedinboththerotenoneandMPTP-inducedtoxin
models. In these models, activation of NADPH oxidase
(NOX2) in microglia occurs. [64, 65]. Furthermore, phar-
macological inhibition of NADPH oxidase is able to protect
mesencephalic dopaminergic neuronal (N27) cells against
MPP+-mediated dopaminergic degeneration [66]. Genetic
models of PD also exhibit increased oxidative stress. In
o n es u c hm o d e l ,l o s so fP I N K 1f u n c t i o ni sa s s o c i a t e dw i t h
increased ROS production by NADPH oxidase in midbrain
neurons. Interestingly, the NADPH oxidase is activated byOxidative Medicine and Cellular Longevity 5
highcytosoliccalciumconcentration,leadingtooverproduc-
tion of superoxide. ROS production from NADPH oxidase
inhibits the plasmalemmal glucose transporter resulting in
deregulation of mitochondrial metabolism [24, 26].
Much less information is available about the role of Xan-
thine Oxidase (XO) in Alzheimer’s or Parkinson’s diseases.
Oxypurinol was able to reduce the production of ROS and
protect neurons in the genetic presenilin 2 mouse model of
AD [67]. In addition, βAi sa b l et oa c t i v a t ep r o d u c t i o no f
H2O2 in cytosol of neocortical neurons [68]. Inhibitor of
XO allopurinol signiﬁcantly suppressed ∗OH generation in
rat striatum of toxic models of Parkinson’s disease induced
by paranonylphenol and MPP(+)[ 69], suggesting a potential
role for XO in the oxidative stress associated with PD.
2.4. Oxidative Stress Results in Selective Neuronal Degenera-
tion. One of the major features of neurodegenerative disease
is the selective vulnerability of diﬀerent neuronal popula-
tions that are aﬀected in a progressive and often stereotyped
manner.However,thesusceptibleneuronalpopulationvaries
between diseases, despite oxidative stress being implicated
as the major pathogenic process in all of them. Thus, the
most vulnerable regions of the brain aﬀected in AD such
as the entorhinal cortex and the hippocampus CA1 region
diﬀer from the most vulnerable regions aﬀected in PD which
includes the dopaminergic neurons in the substantia nigra.
Even within a region, the subset of neurons aﬀected will be
adjacent to a subset of neurons that are spared; for example,
in PD, the SNpc dopaminergic neurons are aﬀected while
the VTA neurons are spared. Therefore, in addition to a
global oxidative stress that aﬀects all neurons, there must be
additional factors that determine the selective cell death in
each disease.
Certain neuronal groups have high intrinsic levels of
oxidative stress and are therefore more vulnerable to addi-
tional disease-related oxidative stress. Neurons that have
long axons and multiple synapses have high bioenergetic
requirements for axonal transport or long-term plasticity.
A high ATP demand combined with relative mitochondrial
dysfunction will render these groups of neurons far more
sensitive to degeneration than other neuronal groups. Dif-
ferent neuronal groups exhibit diﬀerent degrees of oxidative
stress. For example, in the hippocampus CA1 neurons
generate higher levels of superoxide anion than CA3 neurons
and exhibit higher levels of expression of both antioxidant
and ROS-producing genes [70]. Neurons that are exposed
to higher levels of cytosolic dopamine; that is, dopaminergic
neurons are also exposed to additional oxidative stress
produced by the metabolism of dopamine by MAO (which
generates hydrogen peroxide) as well as the autooxidation of
dopamine (which generates superoxide). Thus endogenous
dopamine, as well as exogenous treatment with levodopa
(used in PD) may be a further source of oxidative stress that
may worsen pathogenesis [71, 72]. Higher levels of intrinsic
oxidative stress may result in mitochondrial dysfunction,
which further results in the production of more free radicals
and an exacerbation of the cycle of oxidative stress. However,
it should be noted that the MAO-induced metabolism
of dopamine and production of hydrogen peroxide have
an important role in physiological calcium signaling in
astrocytes and is not solely a pathological process [73].
Therefore, it is possible that antioxidant treatment may also
have an eﬀect on normal signal transmission in the brain.
One interesting hypothesis for the vulnerability of spe-
ciﬁc neuronal groups in Parkinson’s disease has emerged
from the discovery that adult substantia nigra pars compacta
dopaminergic neurons have an autonomous pacemaker
mechanism that utilizes L-type calcium channels resulting
in intracellular calcium oscillations. This creates a metabolic
stress for such neurons as the repeated and persistent entry
of calcium into cells needs to be counterbalanced by ATP
demanding pumps to restore the calcium concentration. In
fact it has been demonstrated that the opening of these L-
type ion channels results in higher levels of oxidative stress
in the mitochondria of such neurons [74]. Moreover, other
nondopaminergic groups of neurons that are also selectively
aﬀected in PD such as the dorsal motor nucleus of the vagus,
the serotonergic neurons of the raphe nuclei, and neurons
of the locus coeruleus all engage the same L-type calcium
channel pacing mechanism. Therefore, this represents an
exampleof acell-speciﬁcfactorthatrenderscertainneuronal
groups highly vulnerable to the disease process.
2.5. Use of Antioxidant Therapy in Neurodegenerative Disease.
Based on the hypothesis that oxidative stress is pathogenic
in neurodegenerative disease, the rationale for the use of
antioxidants as therapies is clear. And indeed the initial de-
monstrationofthebeneﬁtsofantioxidantsinanimalandcell
models of disease was promising. Perhaps the most widely
studied of these antioxidant therapies have been vitamin E
(the major scavenger of lipid peroxidation in brain), vitamin
C (intracellular reducing molecule), and coenzyme Q10
(transfers electrons from complexes I and II to complex III
in respiratory chain).
Vitamin E supplementation in an AD mouse model
resulted in improved cognition and reduced βA deposition
[75]. The reduction of amyloid deposition was particularly
n o t e di ny o u n gA Dm i c e[ 76]. Daily injections of vitamin C
in the APP/presenilin 1 mouse model signiﬁcantly reduced
memory deﬁcits.
Conversely, vitamin E has not been shown to have a
protective eﬀect in the commonly used toxin-based model
of MPTP-induced PD. However, the molecule coenzyme
Q10 has been shown to have multiple protective eﬀects
withinthemitochondriaandthereforehasbeenwidelytested
as a potential therapy. Administration of CoQ10 protects
MPTP-treated mice from dopaminergic neuronal loss and
also attenuated α-synuclein aggregation. Neuroprotection by
CoQ10 in an MPTP-primate model has also been reported
[77].
Despite the promise of these animal studies, there has
been no proven beneﬁt for the use of vitamin E and/or vita-
min C in either AD or PD from large randomised controlled
trials [78] .T h e s et r i a l sh a v eb e e nr e v i e w e di nd e t a i li n
[79, 80]. Furthermore, a large meta-analysis of vitamin E
clinical trials, CoQ10 trials, and a glutathione trial in PD
concluded that there were only minor treatment beneﬁts in
the CoQ10 trials that may have been due to improvement in6 Oxidative Medicine and Cellular Longevity
the respiratory chain deﬁcit rather than a direct antioxidant
action [81]. None of the trials have shown signiﬁcant beneﬁt
to warrant recommendation for use in the clinical setting.
The disappointing translation of the oxidative stress
hypothesis into useful therapy in human disease raises
several issues regarding extrapolation of results from ani-
mal studies to the clinical setting. All animal models are
limited in recreating the human disease as they do not
recapitulate the long-time frame and gradual accumulation
of age-related changes that characterise late onset sporadic
neurodegenerative diseases in humans. From much of the
animal model data, it appears that antioxidants must be
administered at an early stage in the disease where the
process inﬂuences pathogenesis most, and therefore the
use of antioxidants in established late disease in humans
may be ineﬀective. There are several pharmacodynamic and
pharmacokineticconsiderationssuchasthebioavailabilityof
reducing molecules in the human brain in the doses used
in animal models and furthermore the eﬀective targeting
of such molecules to the mitochondria in human brain.
Manytherapies have used antioxidants thatactas scavengers,
rather than blocking the source of the ROS production, and
this may be less eﬀective. Finally it is possible that there
are several diﬀerent producers of oxidative stress in each
disease, and that these may need to be targeted separately but
simultaneously by multiple therapies in order to eﬀectively
reduce oxidative stress and slow disease progression.
There are many processes that have been implicated
in the pathogenesis of neurodegeneration including pro-
tein misfolding and aggregation, abnormal kinase-signalling
pathways, neuronal calcium dysregulation, and impaired
synaptic transmission. Many of these interact with, and are
exacerbated by, oxidative stress. With the mounting robust
evidence of the role of oxidative stress in pathogenesis, it
remains likely that the hypothesis that oxidative damage
is critical in disease is indeed true, and moreover that
careful targeting of this process should serve to ameliorate
neurodegenerative disease.
3.BOX 1:ROS ProducersinMammalianBrain
3.1. NADPH Oxidase. NADPH oxidase is a multisubunit
enzyme complex that was ﬁrst described in phagocytes [82].
NADPH oxidase is a member of the NOX gene family,
also called NOX2 and phagocytic oxidase (PHOX). Seven
NOX genes have been identiﬁed: NOX1 to 5 and DUOX1
and 2. Very little is known about the role of NOX5 and
DUOX1 and 2 in the CNS. The majority of the NOX
enzyme expressed in the brain is NOX2 although some
evidenceexistsfortheCNSlocalizationofNOX1,NOX4,and
possibly also NOX3. The NOX2 enzyme complex consists
of the membrane-bound cytochrome b558 (p22PHOX and
the enzymatic subunit, gp91PHOX), several cytosolic proteins
(p47PHOX,p 6 7 PHOX, and p40PHOX), and the Rac G-protein.
NADPH oxidase is activated when the cytosolic subunits are
phosphorylated and Rac is activated in the cytosol, resulting
in their translocation to the membrane and formation of
the active NADPH oxidase complex with cytochrome b558
[83]. The enzyme transfers the proton across the membrane,
and the end product of the enzyme is superoxide. The NOX
family of proteins is expressed on diverse cell types, and
NADPH oxidase is present in microglia [84], neurons, and
astrocytes [85, 86]. The physiological role of NOX enzymes
in brain cells is still unclear and described mostly as an eﬀect
of superoxide produced by NADPH oxidase [87].
3.2. Xanthine Oxidase. Xanthine oxidase or xanthine dehy-
drogenase are two convertible forms of Xanthine oxidore-
ductase. It is a complex molybdoﬂavoenzyme that is readily
available from milk and widely distributed in mammalian
tissues and is generally accepted to be a key enzyme of purine
catabolism [88]. XO catalyses the oxidation of a wide range
of substrates and can pass electrons to molecular oxygen
to produce uric acid, superoxide, and hydrogen peroxide.
Under normal conditions the enzyme exists in the form of
xanthinedihydrogenase.Ca2+-stimulatedproteasescausethe
irreversible partial cleavage of xanthine dehydrogenase to
xanthine oxidase, which in turn catalyzes the oxidation of
hypoxanthine to xanthine.
The role of XO in ischaemic cell injury was demonstrated
in the 1980’s. Deprivation of oxygen leads to the metabolism
of ATP and accumulation of hypoxanthine. Hypoxia induces
a rise in the levels of intracellular calcium, which activates a
protease that converts XDH, predominantly in vivo, into XO.
Concomitantly, purines are catabolised, and hypoxanthine
accumulates. On reperfusion, oxygen is again available and,
in the presence of XO and hypoxanthine, is reduced to
hydrogen peroxide and superoxide [88, 89].
3.3. Mitochondria. It has become dogma that mitochondria
are a major source of ROS. In pathological conditions, this
organelle actually produces less-free radicals than cytosolic
enzymes such as NADPH oxidase. However, mitochondria
(electron transport chain-ETC), in contrast to other cellular
producers of ROS, generate free radicals all the time.
Mitochondria, which harbor the bulk of oxidative pathways,
are packed with various redox carriers and centers that
can potentially leak single electrons to oxygen and convert
it into superoxide anion, a progenitor ROS. The initial
observations of ROS production in mitochondrial fragments
came as early as 1966 but passed almost unnoticed until
1971 when Loschen, Flohe, and Chance demonstrated for
the ﬁrst time that succinate supported H2O2 production by
intact pigeon heart mitochondria [90–92]. Depending on
the metabolic conditions, isolated mitochondria produced
superoxide in respiratory complex I (in the direction of the
matrix), complex III (in direction of matrix and to outside
of matrix) [90]. ROS in mitochondria can also be generated
in several enzymes including aconitase and α-ketoglutarate
dehydrogenase complex [90, 93]. The production of super-
oxide by the ETC in mitochondria is dependent on the value
of mitochondrial membrane potential.
Because of the constant production of free radicals,
mitochondria possess a very eﬃcient antioxidant system in
the matrix. Overproduction of ROS in mitochondria or in
other sources and changes in the antioxidant system lead toOxidative Medicine and Cellular Longevity 7
imbalance and induce oxidative stress and neurodegenera-
tion.
Inhibition of neuronal respiration by oxygen deprivation
or chemical ischemia leads to a signiﬁcant increase in the
generation of ROS in mitochondria [94]. This eﬀect can be
reduced by the application of mitochondrial uncouplers, and
a number of reports have demonstrated signiﬁcant neuro-
protection by mild uncoupling with UCP2 in cerebral stroke
[95]. In addition, mutations in mitochondrial complexes I–
IV induce inhibition of respiration and activation of ROS
production [96, 97] and selective neuronal cell death [98].
3.4. Monoamine Oxidase. The mitochondrially located
(outer membrane) ﬂavoenzymes monoamine oxidase A
(MAO A) and monoamine oxidase B (MAOB) represent one
of the most extensively studied enzyme group. This long-
term interest stems from their role in the oxidative cataboli-
sm of important amine neurotransmitters, including seroto-
nin, dopamine, and epinephrine [99]. MAO-A and MAO-B
are encoded by separate genes that correspond to diﬀerent
amino acid sequences that are ∼70% identical. In the CNS
theyareexpressedinneurons(MAO-A)andglialcells(MAO
A and B). MAO breaks down monoamines using FAD and
results in the production of aldehydes. The FAD-FADH2 cy-
cle generates hydrogen peroxide.
4.BOX 2:The AntioxidantSystem
4.1.AntioxidantSystem. CellularlevelsofROSarecontrolled
by antioxidant enzymes and small-molecule antioxidants.
4.1.1. Superoxide Dismutase. As major antioxidant enzymes,
superoxide dismutases (SODs), play a crucial role in scav-
enging O
•−
2 . The superoxide dismutase family is specializ-
ed in eliminating superoxide anion radicals derived from
extracellular stimulants, including ionizing radiation and
oxidative insults, together with those primarily produced
within the mitochondrial matrix as byproducts of oxygen
metabolism through the electron transport chain [100].
Three distinct isoforms of SOD have been identiﬁed and
characterized in mammals: copper-zinc superoxide dismu-
tase (Cu/ZnSOD; encoded by the sod1 gene), manganese
superoxide dismutase (MnSOD; encoded by the sod2 gene),
andextracellularsuperoxidedismutase(ECSOD;encodedby
thesod3gene).TheseformsofSODexhibitsimilarfunctions,
but characteristics of their protein structure, chromosome
localization, metal cofactor requirements, gene distribution,
and cellular compartmentalization are distinctly diﬀerent
from one another [100].
4.1.2. Glutathione Peroxidases. Glutathione peroxidase is the
general name for a family of multiple isozymes that catalyze
the reduction of H2O2 or organic hydroperoxides to water
or corresponding alcohols using reduced glutathione (GSH)
as an electron donor (H2O2 +2 G S H→ GS-SG + 2H2O).
In mammalian tissues, there are four major selenium-de-
pendent glutathione peroxidases (GPX) and phospholipid
hydroperoxide glutathione peroxidase, which incorporates
cysteine instead of selenocysteine in the conserved catalytic
motif [101]. GPX1 is known to localize primarily in glial
cells, in which GP activity is tenfold higher than in neurons
[101].
4.1.3. Catalase. Catalase is a ferriheme-containing enzyme
that is responsible for the conversion of hydrogen peroxide
(but not other peroxides) to water [5]. It is localised in pero-
xisomes and may also be found in cytoplasm and mito-
chondria.Ithasaminorroleatlowlevelsofhydrogenperoxi-
de generation but becomes more important at higher levels
of hydrogen peroxide production.
4.2. Nonenzymatic Antioxidants.
4.2.1. GSH. The main antioxidant in CNS, glutathione
(GSH), is the most abundant small molecule, nonprotein
thiol in cells (present in millimolar concentration in the
brain) [102]. It consists of a tripeptide of glutamate, cysteine
and glycine characterized by a reactive thiol group and
γ-glutamyl bond. Reduced GSH can nonenzymatically act
directly with free radicals, notably superoxide radicals,
hydroxyl radicals, nitric oxide, and carbon radicals for their
removal. GSH peroxidase and GSH reductase can act enzy-
matically to remove H2O2 and maintain GSH in a reduced
state [102].
4.2.2.VitaminE. TheroleofvitaminEinthecentralnervous
system is not fully understood although it is a lipid soluble
molecule with antioxidant function. It appears to neutralize
theeﬀectofperoxideandpreventlipidperoxidationinmem-
branes.
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